

## Nepal Support for Rotavirus Vaccine

**This Decision Letter sets out the Programme Terms of a Programme.**

<b>1. Country:</b> Nepal					
<b>2. Grant number(s):</b> 1821-NPL-13b-X / 18-NPL-08b-Y					
<b>3. Date of Decision Letter:</b> 27 March 2019					
<b>4. Date of the Partnership Framework Agreement:</b> 22 August 2014					
<b>5. Programme title:</b> New Vaccine Support (NVS), Rotavirus Routine					
<b>6. Vaccine type:</b> Rotavirus					
<b>7. Requested product presentation and formulation of vaccine:</b> Rotavirus, 2 dose(s) schedule					
<b>8. Programme duration<sup>1</sup>:</b> 2018 -2021					
<b>9. Programme Budget (indicative):</b> (subject to the terms of the Partnership Framework Agreement)					
	2018	2019	2020	2021	Total <sup>2</sup>
Programme Budget (US\$)	0	0	0	0	0
<b>10. Vaccine introduction grant (in US\$):</b> Not applicable					
<b>11. Product switch grant:</b> Not applicable					
<b>12. Indicative Annual Amounts:</b> (subject to the terms of the Partnership Framework Agreement) <sup>3</sup>					
Type of supplies to be purchased with Gavi funds in each year	2018	2019			
Number of Rotavirus vaccines doses	0	0			
Annual Amounts (US\$)	0	0			
<b>13. Procurement agency:</b> UNICEF Country shall release its co-financing payments each year to UNICEF.					
<b>14. Self-procurement:</b> Not applicable					

<sup>1</sup> This is the entire duration of the Programme.

<sup>2</sup> This is the total amount endorsed by Gavi for the entire duration of the Programme. The amount is de-committed in the context of the unavailability of the requested product presentation.

<sup>3</sup> The annual amounts for 2018 and 2019 have been amended to reflect the unavailability of the requested product presentation.

<p><b>15. Co-financing obligations:</b> Reference code: According to the co-financing policy, Country falls within the group Initial self-financing. The following table summarises the co-financing payment(s) and quantity of supply that will be procured with such funds in the relevant year.</p>										
Type of supplies to be purchased with Country funds in each year	2018	2019	2020	2021						
Number of vaccine doses	0	0	0	0						
Value of vaccine doses (US\$)	0	0	0	0						
Total co-financing payments (US\$) (including freight)	0	0	0	0						
<p><b>16. Operational support for campaigns:</b> Not applicable</p>										
<p><b>17. Additional reporting requirements:</b></p> <table border="1"> <thead> <tr> <th>Reports and other information</th> <th>Due dates</th> </tr> </thead> <tbody> <tr> <td>To prepare for the annual procurement of vaccines, Country shall submit the following information each year: <ul style="list-style-type: none"> <li>vaccine stock levels including buffer stock, by end of March;</li> <li>number of children to be vaccinated, wastage rates, any proposed changes in product, presentation or use, or minimum co-financing levels and vaccines received, by mid-May. Countries shall report the actual switch date in the first renewal request following the actual implementation.</li> </ul> </td> <td>31 March 2019 15 May 2019</td> </tr> <tr> <td>In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.</td> <td>To be agreed with Secretariat</td> </tr> </tbody> </table>					Reports and other information	Due dates	To prepare for the annual procurement of vaccines, Country shall submit the following information each year: <ul style="list-style-type: none"> <li>vaccine stock levels including buffer stock, by end of March;</li> <li>number of children to be vaccinated, wastage rates, any proposed changes in product, presentation or use, or minimum co-financing levels and vaccines received, by mid-May. Countries shall report the actual switch date in the first renewal request following the actual implementation.</li> </ul>	31 March 2019 15 May 2019	In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.	To be agreed with Secretariat
Reports and other information	Due dates									
To prepare for the annual procurement of vaccines, Country shall submit the following information each year: <ul style="list-style-type: none"> <li>vaccine stock levels including buffer stock, by end of March;</li> <li>number of children to be vaccinated, wastage rates, any proposed changes in product, presentation or use, or minimum co-financing levels and vaccines received, by mid-May. Countries shall report the actual switch date in the first renewal request following the actual implementation.</li> </ul>	31 March 2019 15 May 2019									
In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.	To be agreed with Secretariat									
<p><b>18. Financial clarifications:</b> Not applicable</p>										
<p><b>19. Other conditions:</b> Not applicable</p>										

Signed by,



**On behalf of Gavi**  
Hind Khatib-Othman  
Managing Director, Country Programmes  
27 March 2019